American heart journal最新文献

{"title":"Fitbit-measured physical activity is inversely associated with incident atrial fibrillation among All of Us participants.","authors":"Souptik Barua, Dhairya Upadhyay, Aditya Surapaneni, Morgan Grams, Lior Jankelson, Sean Heffron","doi":"10.1016/j.ahj.2025.05.003","DOIUrl":"https://doi.org/10.1016/j.ahj.2025.05.003","url":null,"abstract":"<p><strong>Background: </strong>Individuals who report meeting weekly moderate to vigorous physical activity (MVPA) guidelines have lower risk of atrial fibrillation (AF). However existing studies have relied on subjective questionnaires or short-duration (<1 week) objective assessments using accelerometry. The objective of this research was to investigate an association between MVPA levels and the incidence of AF, utilizing long-term, free-living accelerometry data.</p><p><strong>Methods: </strong>1-year Fitbit data, in addition to survey and electronic health record (EHR) data, were extracted from the NIH All of Us (AoU) research database. Cox proportional hazards regression was used to model the association of average MVPA and incident AF over a five-year follow-up period.</p><p><strong>Results: </strong>15570 AoU participants were included (52±16 years, 71% female, 79% White, BMI 28.9±5.0 kg/m², 41±12 complete weeks of Fitbit wear). 97 individuals (0.6%) experienced incident AF in the five-year follow-up period. Every additional hour of MVPA was associated with 8% lower AF risk (HR = 0.92 [0.86,0.99], p=0.02). In a subset of 10533 participants with genomic data, this association persisted after adjustment for AF genetic risk score.</p><p><strong>Conclusions: </strong>Higher amounts of objectively measured MVPA, measured using free-living, long-term accelerometry data, were inversely associated with risk of incident AF, independent of clinical and genetic risk factors.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diversity of Electrocardiographic Patterns in Left Main Culprit Acute ST-Elevation Myocardial Infarction.","authors":"B Rai, M Yildiz, S Bergstedt, A Bandari, D Niehaus, A Bae, K R Thao, A Matos, T D Henry, R F Garberich, J Chambers, A Murthy, S W Sharkey, F V Aguirre","doi":"10.1016/j.ahj.2025.05.007","DOIUrl":"https://doi.org/10.1016/j.ahj.2025.05.007","url":null,"abstract":"<p><strong>Background: </strong>The clinical implications of diverse electrocardiographic (ECG) findings in acute ST-elevation myocardial infarction (STEMI) patients with left main (LM) culprit are not well understood.</p><p><strong>Methods: </strong>Using the multicenter Midwest STEMI consortium database of 12,403 patients, we identified 68 (0.5%) with unprotected LM culprits. The activating ECGs (aECG) were classified into three patterns: a) Non-ST-elevation (NSTE); b) ST-elevation (STE); or c) Atypical.</p><p><strong>Results: </strong>The median age was 68 (IQ percentile: 58-83) years, 67% were male. LM occlusion (TIMI flow: 0-1) was observed in 20 (29%) and sub-occlusive LM (TIMI flow: 2-3) in 48 (71%) patients. Worse in-hospital adverse outcomes (cardiac arrest: 50% vs. 18%, p=0.016; shock: 75% vs. 36%, p=0.007; and death, 75% vs. 44%, p=0.03) occurred among patients with an occlusive versus sub-occlusive LM culprit, respectively. Both a NSTE-type (n=14; 20.5%) and STE-type (n=14; 20.5%) aECG pattern were observed in the minority of patients limiting the diagnostic utility for identifying the presence of LM culprit acute myocardial infarction (aggregate sensitivity: 41%; specificity:71%). A STE-type aECG was more frequently associated with LM occlusion (n=10/14; 71%) compared with either a NSTE- or Atypical-type ECG pattern (10/54; 19%; p=0.001; aggregate sensitivity: 50%, specificity: 92%) and higher adverse in-hospital cardiac events.</p><p><strong>Conclusion: </strong>Previously reported archetypal ECG patterns associated with LM culprit MI were observed in a minority of patients, limiting thier diagnostic utility. A STE-type pattern more accurately detected the presence of occlusive LM coronary flow and was associated with worse in-hospital outcomes.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of delayed percutaneous coronary intervention for STEMI in the Southeast United States.","authors":"Maxwell C Messinger, Nicklaus P Ashburn, Joshua S Chait, Anna C Snavely, Siena Hapig-Ward, Jason P Stopyra, Simon A Mahler","doi":"10.1016/j.ahj.2025.05.002","DOIUrl":"https://doi.org/10.1016/j.ahj.2025.05.002","url":null,"abstract":"<p><strong>Background: </strong>While percutaneous coronary intervention (PCI) reperfusion within 90 minutes of first medical contact (FMC) is indicated for ST-segment elevation myocardial infarction (STEMI), long transport times in rural areas can make this unlikely. We sought to quantify Southeast US residents at risk of treatment delay due to transport.</p><p><strong>Methods: </strong>A cross-sectional study of Southeast US residents was conducted using American Community Survey data and geographic information systems (GIS) to estimate emergency medical services (EMS) transport times to primary PCI (PPCI) centers. All PPCI centers in the study area were included, as well as centers in surrounding states. The main outcomes were the number of residents residing more than 30 and 60 minutes from PPCI. These cutoffs are based on national median EMS scene times and door-to-device times and correspond to estimated FMC-to-device times of 90 and 120 minutes, respectively. A secondary outcome was identification of counties with greater than 50% and 90% of their population at risk of treatment delay.</p><p><strong>Results: </strong>Of 62,880,528 residents in the study area, we identified nearly 11 million at risk of delayed PCI (17.3%, 10,866,710 ± 58,143). Of those, 1,271,522 (± 51,858) live greater than 60 minutes from PPCI. We found that 8.4% (52/616) of counties have more than 50% of their population at risk of treatment delay. 42.3% (22/52) of those have more than 90% of at risk.</p><p><strong>Conclusions: </strong>Nearly 11 million people in the Southeast US do not have timely access to PCI. This disparity may contribute to increased morbidity and mortality.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digoxin in rheumatic heart disease - Rationale and design of a multi-centre, placebo controlled double blind randomised controlled trial (Dig-RHD trial).","authors":"Niveditha Devasenapathy, Shyamashree Biswas, Prayaag Kini, Santhosh Satheesh, Mohit D Gupta, Girish Mp, Rishi Sethi, Satyavir Yadav, Sanjeev Asotra, Arun Gopalakrishnan, Sudeep Gupta, Aditya Kapoor, Chandra Bhan Meena, Ravi S Math, Shanmugam Krishnan, Sandeep Bansal, Nagendra Boopathy, Romika Jhajhria, Birbal Kaushik, Nitya Wadhwa, Manoj Soni, Aman Rastogi, Arpita Ghosh, Vivekanand Jha, Ganesan Karthikeyan","doi":"10.1016/j.ahj.2025.05.005","DOIUrl":"https://doi.org/10.1016/j.ahj.2025.05.005","url":null,"abstract":"<p><strong>Background: </strong>Rheumatic heart disease (RHD), is a public health problem in low and middle-income countries. It causes high morbidity and mortality due to heart failure (HF), but there are no randomised trials of HF-treatments in these patients. Digoxin is an inexpensive drug that is widely used in RHD despite a lack of data on its effect on clinical outcomes. The Digoxin in RHD (Dig-RHD) trial will evaluate the impact of the drug on clinical outcomes in patients with RHD.</p><p><strong>Methods: </strong>The Dig-RHD trial is an investigator-initiated multi-centre, pragmatic, randomized placebo-controlled, parallel-arm, superiority trial. Symptomatic adult patients with RHD were randomized to receive oral digoxin or matching placebo on a background of usual care. The primary outcome is a composite of all-cause death, new-onset or worsening HF. Key secondary outcomes are, all-cause death, HF-related death, hospitalization for HF, sudden death, and self-reported quality of life. Patients were enrolled at 12 academic medical centres in India, beginning in February 2022. Enrolment of 1769 patients was completed in August 2024. One interim review of the data by the independent Data Safety Monitoring Board, after half the primary outcome events had accrued, indicated no safety signals. The last follow-up visits are scheduled to complete in December 2025.</p><p><strong>Conclusion: </strong>Dig-RHD is the first randomized trial of digoxin in RHD powered for clinical outcomes, and the results will have major implications for the routine management of patients with RHD. (Clinical trial registration: CTRI/2021/04/032858).</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ``Transcoronary cooling and dilution for cardioprotection during revascularisation for ST-segment elevation myocardial infarction: design and rationale of the STEMI-Cool study''. [Am Heart J. 2025:282:40-50]","authors":"Ermes Carulli ,&nbsp;Michael McGarvey ,&nbsp;Mohssen Chabok ,&nbsp;Vasileios Panoulas ,&nbsp;Gareth Rosser ,&nbsp;Mohammed Akhtar ,&nbsp;Robert Smith ,&nbsp;Navin Chandra ,&nbsp;Abtehale Al-Hussaini ,&nbsp;Tito Kabir ,&nbsp;Laura Barker ,&nbsp;Francesco Bruno ,&nbsp;Konstantinos Konstantinou ,&nbsp;Ranil de Silva ,&nbsp;Jonathan Hill ,&nbsp;Yun Xu ,&nbsp;Rebecca Lane ,&nbsp;Chiara Bucciarelli-Ducci ,&nbsp;Thomas Luescher ,&nbsp;Miles Dalby","doi":"10.1016/j.ahj.2025.04.025","DOIUrl":"10.1016/j.ahj.2025.04.025","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"288 ","pages":"Page 89"},"PeriodicalIF":3.7,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143921916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Once-Weekly Subcutaneous Semaglutide on Arterial Inflammation in People with Type 2 Diabetes and Cardiovascular Disease Using PET-MRI: Primary Results of a Randomized, Double-Blind, Placebo-Controlled Trial.","authors":"Stefan James, Andreas Dyreborg Christoffersen, Jens-Peter David, Marcus Hacker, Maria D Radu Juul Jensen, Linda Mellbin, Thomas R Pieber, Rasmus Sejersten Ripa, Peter Rossing, Eva Svehlikova, Andreas Kjaer","doi":"10.1016/j.ahj.2025.05.001","DOIUrl":"https://doi.org/10.1016/j.ahj.2025.05.001","url":null,"abstract":"<p><strong>Background: </strong>Semaglutide has demonstrated cardiovascular benefits in people with type 2 diabetes (T2D) with cardiovascular disease (CVD). Inflammation plays a well-documented role in atherosclerosis and glucagon-like peptide-1 receptor agonists, like semaglutide, have shown anti-inflammatory effects in animal and clinical studies. This trial investigated the effect of semaglutide on atherosclerotic inflammation in the carotid arteries using positron emission tomography (PET)-magnetic resonance imaging (MRI).</p><p><strong>Methods: </strong>Patients with T2D and CVD were randomized to double-blinded once-weekly subcutaneous semaglutide 1.0 mg or placebo. The primary and key secondary endpoints used PET-MRI with [¹⁸F]FDG and [⁶⁸Ga]DOTATATE tracers to assess change from baseline to week 26 in plaque inflammation in the segments of the carotid arteries that were determined to be the most diseased and where plaque inflammation was quantified by the maximum target-to-background ratio (TBR_max) of the tracers. Additional secondary endpoints assessed plaque morphology and burden using MRI at week 52, including total wall volume, lipid-rich necrotic core volume, and fibrous cap thickness.</p><p><strong>Results: </strong>Of 101 patients, 87.1% were male, mean age was 66 years and they were well-treated according to guidelines. No significant treatment differences were observed between semaglutide and placebo for change in plaque inflammation at week 26 with either tracer; TBR_max of FDG (estimated treatment difference [ETD]: 0.033, 95% confidence interval [CI]: -0.118;0.184) and [⁶⁸Ga]DOTATATE (ETD: 0.045, 95% CI: -‍0.314;0.404).</p><p><strong>Conclusions: </strong>This trial explored the feasibility of following plaque inflammation with PET-MRI using [¹⁸F]FDG and [⁶⁸Ga]DOTATATE. A significant effect of semaglutide versus placebo on carotid plaque inflammation could not be detected through the methodology used in this trial, likely due to minimal baseline inflammation. However, this does not exclude an effect of semaglutide on inflammation seen in previous preclinical and clinical studies.</p><p><strong>Trial registration: </strong>URL: https://www.</p><p><strong>Clinicaltrials: </strong>gov; Unique identifier: NCT04032197.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S0002-8703(25)00149-8","DOIUrl":"10.1016/S0002-8703(25)00149-8","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"286 ","pages":"Page iv"},"PeriodicalIF":3.7,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143905835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loop and thiazide diuretics and outcomes in heart failure with preserved ejection fraction.","authors":"Barna Szabó-Söderberg, Lina Benson, Gianluigi Savarese, Camilla Hage, Federica Guidetti, Tonje Thorvaldsen, Bertram Pitt, Lars H Lund","doi":"10.1016/j.ahj.2025.04.029","DOIUrl":"https://doi.org/10.1016/j.ahj.2025.04.029","url":null,"abstract":"<p><strong>Background: </strong>Trials in heart failure with preserved ejection fraction (HFpEF) frequently apply baseline diuretic use as enrichment criterion. However, the role of thiazides and loop diuretic dose for enrichment is unclear. We aimed to assess baseline loop and thiazide diuretic use, loop diuretic dose, and associations with cardiovascular (CV) outcomes in HFpEF.</p><p><strong>Methods: </strong>We performed a post-hoc analysis of TOPCAT-Americas. The primary outcome was CV death and total hospitalizations for heart failure (HHF).</p><p><strong>Results: </strong>1765 patients were followed for a median of 2.9 years. At baseline, loop diuretic monotherapy was used in 67%, thiazide monotherapy in 10% and the combination in 12%. Loop diuretic monotherapy and combined loop+thiazide diuretic treatment were associated with higher risk of the primary outcome (HR 1.59, 95% CI 1.23-2.07, p<0.001; and HR 2.07, 95% CI 1.55-2.76, p<0.001 respectively), as well as first HHF, total HHFs and the composite of first HHF or CV death. Only combined loop+thiazide diuretic therapy was associated with CV death alone (HR 1.85, 95% CI 1.13-3.04, p=0.015). For all above endpoints, the combined diuretic therapy was associated with greater risk than loop diuretics alone. Thiazide monotherapy was not associated with any endpoints. Higher baseline loop diuretic doses were associated with higher risk of all outcomes.</p><p><strong>Conclusion: </strong>In HFpEF, baseline use and higher doses of loop diuretics were associated with higher risk of CV death and total HHFs. Thiazide alone was not associated with any endpoints, but when added to loop diuretics it was associated with additional risk for all outcomes.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incremental role of late gadolinium enhancement in risk stratifying high risk patients with hypertrophic cardiomyopathy.","authors":"Srekar N Ravi, Michael O'Shea, Omar Baqal, Olubadewa A Fatunde, Juliana Savic, Danielle B Green, Suganya Arunachalam, Ahmed Ibrahim, Linda Schwartz, Jeffrey B Geske, Konstantinos C Siontis, Michael Ackerman, Steve Ommen, Clinton E Jokerst, Reza Arsanjani, Said Alsidawi","doi":"10.1016/j.ahj.2025.04.030","DOIUrl":"https://doi.org/10.1016/j.ahj.2025.04.030","url":null,"abstract":"<p><strong>Background: </strong>Current risk stratification models for hypertrophic cardiomyopathy (HCM) rely on a combination of clinical and imaging factors. Recent studies have highlighted the potential role of late gadolinium enhancement (LGE) in enhancing sudden cardiac death (SCD) risk stratification. This study evaluates whether LGE can recalibrate risk stratification models and influence decisions regarding implantable cardioverter-defibrillator (ICD) implantation. We aim to assess the prognostic value of LGE in predicting SCD and its interaction with other established risk factors in patients with HCM.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of HCM patients from a multi-site referral center who underwent CMR imaging and had ICDs implanted. We analyzed the incidence of appropriate ICD discharges with LGE presence as an effect modifier.</p><p><strong>Results: </strong>Out of 326 participants, 50 experienced at least one appropriate ICD discharge over the study period. LGE >15% by itself was significantly associated with a higher rate of appropriate discharges, and significantly adjusted the risk of appropriate discharges in clinical indications such as a family history of SCD and syncope. The study did not find LGE to enhance appropriate ICD discharge risk in patients with already high risk based on imaging features or nonsustained ventricular tachycardia on ambulatory monitoring.</p><p><strong>Conclusions: </strong>LGE provides incremental prognostic value in refining risk stratification for SCD in HCM patients, especially when the decision for ICD placement may be clinical history alone. This study supports integrating LGE assessments into routine clinical practice to improve the precision of ICD decision-making.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Data quality assessment in the SWEDEHEART registry: Insights from serial audits on completeness and accuracy.","authors":"Margret Leosdottir, Lars Dahlbom, Maria Bäck, Lars Wallentin, Joakim Alfredsson, David Erlinge, Tomas Jernberg, Emil Hagström","doi":"10.1016/j.ahj.2025.04.028","DOIUrl":"https://doi.org/10.1016/j.ahj.2025.04.028","url":null,"abstract":"<p><strong>Background: </strong>Registry data used to monitor clinical care need to be reliable, and the process for assuring data quality transparent. Here the auditing process of the Swedish quality registry for cardiac disease, SWEDEHEART, is described.</p><p><strong>Methods: </strong>SWEDEHEART audits have been performed at four time-points in 2011-2018, with data quality audited in the three largest sub-registries covering acute coronary syndromes (ACS), percutaneous coronary interventions (PCI), and cardiac rehabilitation (CR). Data is audited against electronic medical records by four controllers, centrally coordinated by a project leader. During the 2011 audit 13/71 (18.3%) of ACS-admitting hospitals and 8/28 (28.6%) of coronary catheterization labs reporting to the registry were audited. During the 2017-2018 audit all reporting sites (100.0%) were audited: 72 hospitals, 30 catheterization labs, and 75 CR centres, with more than 200,000 data points controlled. Results Overall data completeness in the 2017-2018 audit was as follows: SWEDEHEART-ACS 99.1%, SWEDEHEART-PCI 99.2%, and SWEDEHEART-CR 94.5%. The accuracy of registry data compared to electronic medical records was >95.0% for all sub-registries at all four audits (p for trend <0.0001), in 2017-2018 as follows: SWEDEHEART-ACS 97.5%, SWEDEHEART-PCI 98.4%, and SWEDEHEART-CR 95.8%. Data most often incomplete or inconsistent were data on time points, self-reported data, and data reliant on complex definitions.</p><p><strong>Conclusion: </strong>The SWEDEHEART registry is a highly complete and accurate source of patient characteristics and processes of care, that can be reliably used for quality improvement such as monitoring quality of care, compare hospitals at site- and national level, and include in international comparisons, and for conducting high-quality registry-based research.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}